A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

NCT02985879 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

378

Enrollment

INDUSTRY

Sponsor class

Stopped This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy of study drug.

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG: Placebo
DRUG: ABBV-8E12

Sponsor

AbbVie